首都医科大学附属北京天坛医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 脊索瘤Chordoma14 篇牵头论文
- 骨肉瘤Osteosarcoma0 篇牵头论文
- 神经母细胞瘤Neuroblastoma0 篇牵头论文
- 血友病 AHaemophilia A1 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder34 篇牵头论文牵头 2 项开放试验
- 重症肌无力Myasthenia gravis1 篇牵头论文
- 烟雾病Moyamoya disease60 篇牵头论文牵头 9 项开放试验
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis6 篇牵头论文
- 大动脉炎Takayasu arteritis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis4 篇牵头论文
- 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
- 尼曼-匹克病 C 型Niemann–Pick disease type C0 篇牵头论文
- Leber 遗传性视神经病变Leber hereditary optic neuropathy1 篇牵头论文
未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、肝母细胞瘤、视网膜母细胞瘤、胃肠道间质瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、法布雷病、庞贝病、白塞病、Alport 综合征、IgA 肾病、戈谢病、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 14 篇,占 13.3%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
这些数字背后的记录
牵头的论文14
- Enhancing Chordoma Radiotherapy: Ta@PVP Nanoparticles as Potent Radiosensitizers.
- Development and validation of basement membrane-related signatures for predicting postoperative recurrence, tumor microenvironment and drug candidates in chordomas.
- Radiogenomic method combining DNA methylation profiles and magnetic resonance imaging radiomics predicts patient prognosis in skull base chordoma.
- Endoplasmic reticulum stress-related cancer-associated fibroblast confers adverse prognosis and therapeutic vulnerability in skull base chordoma.
- The novel developed and validated multiparametric MRI-based fusion radiomic and clinicoradiomic models predict the postoperative progression of primary skull base chordoma.
- Function and regulation of miR-186-5p, miR-125b-5p and miR-1260a in chordoma.
- Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
- Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes.
- Mid-term follow-up surgical results in 284 cases of clival chordomas: the risk factors for outcome and tumor recurrence.
- Survival and treatment of cranial and spinal chordomas: a population-based study.
- TGFB3 downregulation causing chordomagenesis and its tumor suppression role maintained by Smad7.
- DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5.
- Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5.
- Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival.
早期论文(2016–2020 年)30
- MRI Signal Intensity and Electron Ultrastructure Classification Predict the Long-Term Outcome of Skull Base Chordomas.
- LncRNA and mRNA expression profiles reveal the potential roles of lncRNA contributing to regulating dural penetration in clival chordoma.
- Mean platelet volume and platelet distribution width serve as prognostic biomarkers in skull base chordoma: a retrospective study.
- High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas.
- A Series of 62 Skull Base Chordomas in Pediatric and Adolescent Patients: Clinical Characteristics, Treatments, and Outcomes.
- Natural Growth Dynamics of Untreated Skull Base Chordomas In Vivo.
- Benign notochordal cell tumour: clinicopathology and molecular profiling of 13 cases.
- Combination of PARP inhibitor and temozolomide to suppress chordoma progression.
- High Expression of TGF-β1 Predicting Tumor Progression in Skull Base Chordomas.
- Differential Diagnosis and Treatment Modality of Parasellar Plasmacytoma: Clinical Series and Literature Review.
- SNF5 as a prognostic factor in skull base chordoma.
- Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.
- Aberrant Expression of Extracellular Signal-Regulated Kinase and 15-Hydroxyprostaglandin Dehydrogenase Indicates Radiation Resistance and Poor Prognosis for Patients with Clival Chordomas.
- MR Imaging Grading System for Skull Base Chordoma.
- Effect comparisons among treatment measures on progression-free survival in patients with skull base chordomas: a retrospective study of 234 post-surgical cases.
- Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients.
- In Reply to the Letter to the Editor Regarding "Expression of Cathepsin K in Skull Base Chordoma".
- In Reply to the Letter to the Editor Regarding "Expression of Cathepsin K in Skull Base Chordoma".
- In Reply to "Ki-67 Index as a Prognostic Marker in Chordomas: A Systematic Review of the Literature".
- In Reply to "Prognostic Significance of Resection Degree in Skull Base Chordoma: A Systematic Review and Meta-Analysis".
- Expression of Cathepsin K in Skull Base Chordoma.
- Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas.
- Clinical Features and Prognostic Factors of Children and Adolescents with Clival Chordomas.
- Factors for Overall Survival in Patients with Skull Base Chordoma: A Retrospective Analysis of 225 Patients.
- Differences in Dural Penetration of Clival Chordomas Are Associated with Different Prognosis and Expression of Platelet-Derived Growth Factor Receptor-β.
- Factors for tumor progression in patients with skull base chordoma.
- Bone invasiveness is associated with prognosis in clivus chordomas.
- Classification and surgical approaches for transnasal endoscopic skull base chordoma resection: a 6-year experience with 161 cases.
- Analysis of Clinical Features and Outcomes of Skull Base Chordoma in Different Age-Groups.
- Proposal and Validation of a Basic Progression Scoring System for Patients with Skull Base Chordoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
骨肉瘤
Osteosarcoma2021–2025 年没有牵头骨肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 24 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 15 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 34 篇,占 7.0%。
北京有 12 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
- 分期
- 未注明
- 开始
- 2019-01
- 登记号
- NCT04106830
年龄 16 岁 至 75 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院北京
- 邀请入组Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
- 分期
- 未注明
- 开始
- 2023-12
- 登记号
- NCT06643858
年龄 6 岁 至 90 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院北京
- 正在招募A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- 分期
- II/III期
- 开始
- 2024-07
- 登记号
- NCT06413654
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙
- 正在招募Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
- 分期
- 早期I期
- 开始
- 2022-04
- 登记号
- NCT05145361
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、天津、太原、西安
- 即将招募Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- 分期
- IV期
- 开始
- 2026-06
- 登记号
- NCT07699770
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心北京、昆明、沈阳、西安、重庆、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文34
- Serum GPR37 as a novel biomarker for disease activity, disability, and differential diagnosis in NMOSD.
- Deep Gray Matter Iron Deposition in NMOSD and MOGAD: A Comparative Study with MS.
- Oligodendroglia in Neuromyelitis Optica Spectrum Disorder.
- Spatiotemporal subtypes of brain and spinal cord atrophy in neuromyelitis optica spectrum disorders and multiple sclerosis.
- Diagnostic biomarkers for differentiating AQP4-IgG- negative NMOSD from other nervous system autoimmune disorders: a retrospective study.
- Estimated Brain Age in Healthy Aging and Across Multiple Neurological Disorders.
- Cerebrospinal fluid interleukin-6 may be a biomarker for conversion of clinically isolated syndrome to neuromyelitis optica spectrum disorder.
- Imaging Transcriptomics of Brain Functional Alterations in MS and Neuromyelitis Optica Spectrum Disorder.
- Identification of potential biomarkers for neuromyelitis optica by quantitative proteomics.
- Distinct virtual histology of grey matter atrophy in four neuroinflammatory diseases.
- Efficacy and safety of apheresis therapy in AQP4 antibody-positive NMOSD attack: A propensity score-matched cohort study.
- The landscape of PBMCs in AQP4-IgG seropositive NMOSD and MOGAD, assessed by high dimensional mass cytometry.
- Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder.
- Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
- Independent and reproducible hippocampal radiomics biomarkers for multisite multiple sclerosis and neuromyelitis optica spectrum disorders.
- APOE from patient-derived astrocytic extracellular vesicles alleviates neuromyelitis optica spectrum disorder in a mouse model.
- Targeting chemoattractant chemokine (C-C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders.
- Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis.
- Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety.
- Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data.
- The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON.
- A prospective study on tryptophan immunoadsorption in AQP4 antibody-positive neuromyelitis optica spectrum disorders.
- Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.
- NMO-IgG Induce Interleukin-6 Release via Activation of the NF-κB Signaling Pathway in Astrocytes.
- Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder.
- Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
- Brain structural and functional alterations in MOG antibody disease.
- Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
- The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis.
- Elevated chemokines and cytokines for eosinophils in neuromyelitis optica spectrum disorders.
- Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
- Timing of plasma exchange for neuromyelitis optica spectrum disorders: A meta-analysis.
- B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease.
- Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
- Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
- Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
- China National Registry of Neuro-Inflammatory Diseases
- Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
- A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
PubMed 以外找到的论文(未计入)5
- Choroid Plexus Cysts on 7T MRI Differentiate NMOSD from MS
- Development and Validation of a Differential Diagnostic Models for Guillain–Barré Syndrome Based on Clinical and Laboratory Indicators: A Retrospective Study
- Progress on single-cell sequencing technology in central nervous system autoimmune diseases
- A Multisite and Multimodal Comparative Study of Cerebellar Connectome Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
- Magnetic resonance imaging markers for multiple sclerosis and neuromyelitis optica spectrum disorders
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 11 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- 分期
- II期
- 开始
- 2022-07
- 登记号
- NCT05067348
年龄 18 岁 至 80 岁(登记的条件)
牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心上海、北京、天津、成都、西安、长沙
- 正在招募A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- 分期
- III期
- 开始
- 2021-07
- 登记号
- NCT04951622
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文1
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
- Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
- The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis
- A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 60 篇,占 16.9%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 8 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
这家医院参与的开放试验 9
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
- 分期
- 不分期
- 开始
- 2026-10
- 登记号
- NCT07889531
年龄 18 岁 至 70 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院北京
- 正在招募Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- 分期
- 未注明
- 开始
- 2026-08
- 登记号
- NCT07894107
年龄 12 岁 至 70 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州
- 正在招募Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
- 分期
- 未注明
- 开始
- 2024-12
- 登记号
- NCT06817434
年龄 18 岁 至 60 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院北京
- 正在招募Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
- 分期
- 未注明
- 开始
- 2024-12
- 登记号
- NCT06832839
年龄 18 岁 至 60 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院北京
- 正在招募Family-Based Moyamoya Susceptibility and Early Detection
- 分期
- 未注明
- 开始
- 2024-11
- 登记号
- NCT07517354
年龄未注明(登记的条件)
牵头:首都医科大学附属北京天坛医院;另有 1 家列出的医院为研究中心北京
- 正在招募Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
- 分期
- 未注明
- 开始
- 2023-10
- 登记号
- NCT06041659
年龄 18 岁 至 65 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院北京
- 正在招募Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
- 分期
- 未注明
- 开始
- 2022-05
- 登记号
- NCT05332756
年龄 2 岁 至 60 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院北京
- 正在招募Registry of Multicenter Brain-Heart Comorbidity in China
- 分期
- 未注明
- 开始
- 2012-01
- 登记号
- NCT05961748
年龄 18 岁 至 未注明(登记的条件)
牵头:首都医科大学附属北京天坛医院;另有 4 家列出的医院为研究中心上海、北京、哈尔滨、郑州
- 即将招募Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
- 分期
- 不分期
- 开始
- 2026-07
- 登记号
- NCT07762547
年龄 18 岁 至 70 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文60
- Integrated bulk RNA sequencing and mass cytometry analysis reveal the circulating immune landscape in ischemic and hemorrhagic Moyamoya disease.
- Serum Creatine Levels as a Predictive Factor for Postoperative Cerebrovascular Events in Patients With Moyamoya Disease.
- Unraveling the Dyslipidemic Landscape in Moyamoya Disease: OxLDL as a Key Biomarker.
- Taurine levels and long-term adverse cerebrovascular risk in moyamoya disease: A prognostic perspective study.
- Innate Immune Cell Profiling in Peripheral Blood Mononuclear Cells of Patients with Moyamoya Disease.
- Circulating T cell atlas in Moyamoya disease: insights into immunopathogenesis of cerebrovascular disorders.
- Serum amyloid A2-induced phenotypic switching of vascular smooth muscle cells in moyamoya disease.
- Improvement in multiple cognitive domains via combined revascularization by 6 months' follow-up: a new potential surgical indication in moyamoya disease.
- RNF213 Variant and Infectious Burden Associated With Intracranial Artery Stenosis in Moyamoya Disease.
- Comprehensive Analysis and In Vitro Verification of Endothelial-Mesenchymal Transition-Related Genes in Moyamoya Disease.
- Choroid plexus enlargement correlates with cognitive dysfunction and disease progression in Moyamoya disease.
- Angiogenesis-related genes and immune microenvironment in moyamoya disease: a transcriptomic and functional analysis.
- Deep-learning tool for early identification of non-traumatic intracranial hemorrhage etiology and application in clinical diagnostics based on computed tomography (CT) scans.
- Reorganization of gray matter networks in patients with Moyamoya disease.
- Understanding external carotid artery collateralisation after cerebral revascularisation in moyamoya disease: insights from quantitative analysis.
- Association Between Folate Metabolism Risk, Collateral Circulation, and Hemorrhagic Risk in Moyamoya Disease.
- Alterations in the Glymphatic System and Association with Brain Structure and Cognitive Function in Moyamoya Disease.
- Glymphatic Impairment Associated with Neurocognitive Dysfunction in Moyamoya Disease.
- Age-Dependent Risk Factors for Hemorrhagic Events in Moyamoya Disease: The Role of Collateral Vessels.
- Differential WNT4 expression among various subtypes of moyamoya disease results in alterations of microtubule stability.
- Circulating immune cell landscape and T-cell abnormalities in patients with moyamoya disease.
- Association of lysine pathway metabolites with moyamoya disease.
- Mass cytometry revealed the circulating immune cell landscape across different Suzuki stages of Moyamoya disease.
- A novel system for evaluating collateralization of the external carotid artery after cerebral revascularization in moyamoya disease.
- Effectiveness of indirect revascularization for adult hemorrhagic moyamoya disease: a 10-year follow-up study.
- Nonalcoholic fatty liver disease is an independent risk factor for ischemic stroke after revascularization in patients with Moyamoya disease: a prospective cohort study.
- Prognostic value of morphology and hemodynamics in moyamoya disease for long-term outcomes and disease progression.
- Characterization of PANoptosis-related genes and the immune landscape in moyamoya disease.
- A Vessel Wall MRI Investigation in Patients With Moyamoya or Quasi-Moyamoya Disease: Diagnosis, Features, and Outcomes.
- Nomogram to Predict Good Neoangiogenesis After Indirect Revascularization Surgery in Patients with Moyamoya Disease: a Case-control Study.
- Risk Factors for Specific Postoperative Ischemic Complications in Patients with Moyamoya Disease: A Single-Center Retrospective Study.
- Long-Term Clinical Outcomes After Cerebral Revascularization in Moyamoya Disease With Extracranial Internal Carotid Artery Occlusion.
- The prognostic nutrition index is a predictor for long-term outcomes after revascularization in adult moyamoya disease.
- Association between systemic immune-inflammatory markers and the risk of moyamoya disease: a case-control study.
- Integrated analysis of the association between methionine cycle and risk of moyamoya disease.
- Metabolomic signatures associated with pathological angiogenesis in moyamoya disease.
- Application of Induced Pluripotent Stem Cells in Moyamoya Disease: Progress and Promises.
- Gut microbiota in adults with moyamoya disease: characteristics and biomarker identification.
- RNA profiling of sEV (small extracellular vesicles)/exosomes reveals biomarkers and vascular endothelial dysplasia with moyamoya disease.
- Fetal posterior cerebral artery in pediatric and adult moyamoya disease: A single-center experience of 480 patients.
- Association between DIAPH1 variant and posterior circulation involvement with Moyamoya disease.
- Upregulated Cytoskeletal Proteins Promote Pathological Angiogenesis in Moyamoya Disease.
- Hemorrhage Risk in Moyamoya Disease with Fetal-Type Posterior Cerebral Artery: A Propensity Score-Matched Analysis.
- Predictors of preoperative cognitive dysfunction in adults with Moyamoya disease: a preliminary research.
- Recurrent Artery of Heubner Aneurysm Masquerading as Caudate Hemorrhage without Subarachnoid Hemorrhage in Moyamoya Disease: A Case Report and Literature Review.
- Infarction Patterns and Recurrent Adverse Cerebrovascular Events in Moyamoya Disease.
- Epigenome-Wide Association Study Reveals Differential Methylation Sites and Association of Gene Expression Regulation with Ischemic Moyamoya Disease in Adults.
- Association of RNF213 Variants With Periventricular Anastomosis in Moyamoya Disease.
- Assessment of Surgical Outcomes in Children and Adult Ischemic Moyamoya Disease and Its Relationship with the Pre-infarction Cerebral Perfusion Status.
- Intraoperative transit-time ultrasonography combined with FLOW800 predicts the occurrence of cerebral hyperperfusion syndrome after direct revascularization of Moyamoya disease: a preliminary study.
- Risk factors for postoperative ischemic complications in pediatric moyamoya disease.
- Changes of cerebral cortical structure and cognitive dysfunction in "healthy hemisphere" after stroke: a study about cortical complexity and sulcus patterns in bilateral ischemic adult moyamoya disease.
- Impairments in brain perfusion, executive control network, topological characteristics, and neurocognition in adult patients with asymptomatic Moyamoya disease.
- Clinical Implications of the "Brush Sign" in Susceptibility-Weighted Imaging for Moyamoya Disease.
- Assessment of blood supply of the external carotid artery in moyamoya disease using super-selective pseudo-continuous arterial spin labeling technique.
- Letter to the Editor Regarding "Clinical Prediction of Surgical Revascularization Outcome in Moyamoya Disease Via Transcranial Color Sonography".
- Hyperhomocysteinemia is a risk factor for postoperative ischemia in adult patients with moyamoya disease.
- Intraoperative local hemodynamic quantitative analysis of direct revascularization in patients with moyamoya disease.
- Effects and safety of aspirin use in patients after cerebrovascular bypass procedures.
- Haemodynamic analysis of adult patients with moyamoya disease: CT perfusion and DSA gradings.
它在 ClinicalTrials.gov 上的全部试验(任何状态)17
- Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
- Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
- Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
- Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
- Family-Based Moyamoya Susceptibility and Early Detection
- Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
- Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
- Registry of Multicenter Brain-Heart Comorbidity in China
- Prognostic Prediction Model in Patients With Moyamoya Disease Undergoing Revascularization Surgery
- Gut Microbiota in Patients With Moyamoya Disease
- The Role of m6A RNA Modification in Moyamoya Disease
- RNF213 Variants and Collateral Vessels in Moyamoya Disease
- Effects of Remote Ischemic Pre-Conditioning in Moyamoya Disease Patients
- Direct Bypass Versus Indirect Bypass in Treatment of Adults Hemorrhagic Moyamoya Disease
- NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events
- Precision Bypass in Patients With Moyamoya Disease
PubMed 以外找到的论文(未计入)7
- Divergent Phenotypes and Persistent Disability: A Comparative Cohort Study of Arterial Ischaemic and Haemorrhagic Stroke in Chinese Paediatric Patients
- 甘油三酯-葡萄糖指数在烟雾病患者中的特征分析:1项病例对照研究(Analysis of Triglyceride-Glucose Index Characteristics in Patients with Moyamoya Disease: A Case-Control Study)
- RNA methylation-driven molecular subtypes and immune infiltration in Moyamoya disease
- Deep Learning Approach to Predict Hemorrhage in Moyamoya Disease
- Deep-Learning Tool for Early Identifying Non-Traumatic Intracranial Hemorrhage Etiology based on CT Scan
- Short⁃term neurological function and clinical symptom improvement after cerebral revascularization in adults with moyamoya disease: a single⁃center study
- A Practical Questionnaire and Literature Review: Dose Suzuki Grading Still the Gold Standard for the Diagnosis of Moyamoya Disease?
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 6 篇,占 2.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 13 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
这些数字背后的记录
牵头的论文6
- Clinical and imaging features and treatment response of anti-NMDAR encephalitis combined with MOGAD.
- Typical metabolic pattern of 18F-FDG PET in Anti-NMDAR encephalitis in the acute and subacute phases and its correlation with T2 FLAIR-MRI features.
- Elevated blood and cerebrospinal fluid biomarkers of microglial activation and blood‒brain barrier disruption in anti-NMDA receptor encephalitis.
- Positron emission tomography in autoimmune encephalitis: Clinical implications and future directions.
- The prognosis of late-onset anti-N-methyl-D-aspartate receptor encephalitis in China.
- Aberrant multimodal brain networks in patients with anti-NMDA receptor encephalitis.
早期论文(2016–2020 年)4
- Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: A retrospective observational study.
- Reply.
- Brain MRI Characteristics of Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Their Associations with 2-Year Clinical Outcome.
- Paraneoplastic Anti-N-Methyl-D-Aspartic Acid Receptor Encephalitis.
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 19 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- 分期
- I期
- 开始
- 2024-12
- 登记号
- NCT06556394
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、成都、杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- The difference between cystatin C- and creatinine-based estimated glomerular filtration rate and survival in amyotrophic lateral sclerosis: a population-based cohort study.
- Genetic evidence for the liver-brain axis: lipid metabolism and neurodegenerative disease risk.
- Amyotrophic lateral sclerosis and myasthenia gravis overlaps syndrome: a series of case report.
- Analysis of lncRNAs profiles associated with ferroptosis can predict prognosis and immune landscape and drug sensitivity in patients with clear cell renal cell carcinoma.
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- Tofacitinib in Patients With Amyotrophic Lateral Sclerosis
- Safety and Tolerance of RAG-17 in Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation
- Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis
- Amyotrophic Lateral Sclerosis Registry
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)
其他疾病
脊髓性肌萎缩症
Spinal muscular atrophy2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 8 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
- 分期
- I/II期
- 开始
- 2024-05
- 登记号
- NCT06421831
年龄 2 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
其他疾病
尼曼-匹克病 C 型
Niemann–Pick disease type C2021–2025 年没有牵头尼曼-匹克病 C 型的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 3 家医院列在尼曼-匹克病 C 型下全国有 15 家医院列在尼曼-匹克病 C 型下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尼曼-匹克病 C 型开放试验。
其他疾病
Leber 遗传性视神经病变
Leber hereditary optic neuropathy2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 3 家医院列在Leber 遗传性视神经病变下全国有 32 家医院列在Leber 遗传性视神经病变下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。
联系这家医院
出示给工作人员或司机的院名卡
首都医科大学附属北京天坛医院
Beijing Tiantan Hospital
北京
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR Wikidata
Beijing Neurosurgical Institute and Beijing Tiantan Hospital; Jing-Jin Center for Neuroinfalmmation Beijing Tiantan Hospital; Tiantan Hospital Affiliated to Capital Medical University; Beijing Tiantan Hospital Affiliated to Capital Medical University; A.L.) and Beijing Tiantan Hospital (F.P; Beijing Tiantan Hospital Capital Medical University; Beijing Tiantan Hospital Affiliated with Capital Medical University; Beijing Tiantan Hospital of Capital Medical University